Jenny Sadler Gallagher

ORCID: 0000-0002-0259-1401 · 15 papers in corpus
2025
·doi:10.1016/j.jpag.2025.01.027
2024
·doi:10.1016/j.jpag.2024.01.147
2024
·doi:10.1016/j.jpag.2024.01.104
observational 2022
PloS one ·doi:10.1371/journal.pone.0269858

Endometriosis affects reproductive-aged females and varies considerably in terms of symptom presentation, morphologic features, and treatment response. Most studies investigating symptom recurrence after an endometriosis-related surgery hav…

observational 2022
Pain ·doi:10.1097/j.pain.0000000000002747

We described trends in pelvic pain characteristics over 2 years of follow-up among adolescents and adults with and without endometriosis participating in the longitudinal observational cohort of the Women's Health Study: From Adolescence to…

rct 2021
F&S reports ·doi:10.1016/j.xfre.2021.07.003

OBJECTIVE: To estimate the efficacy and safety of a novel nonhormonal therapeutic agent, cabergoline, compared with that of the standard clinical therapy, norethindrone acetate (NETA), for the treatment of endometriosis-associated pain in y…

2018
Journal of Pediatric and Adolescent Gynecology ·doi:10.1016/j.jpag.2018.02.074
rct 2018
Journal of Pediatric and Adolescent Gynecology ·doi:10.1016/j.jpag.2018.03.004

STUDY OBJECTIVE: To explore the potential occurrence of long-term side effects and tolerability of gonadotropin-releasing hormone agonist (GnRHa) plus 2 different add-back regimens in adolescent patients with endometriosis. DESIGN: Follow-…

observational 2018
The Journal of adolescent health : official publication of the Society for Adolescent Medicine ·doi:10.1016/j.jadohealth.2018.06.027

PURPOSE: While endometriosis is recognized to have a high patient burden for adults, the level of morbidity it causes for adolescents has been understudied, and may be minimized by clinicians. The purpose of this study was to determine whet…

2016
·doi:10.1016/j.jpag.2016.01.099
rct 2016
Journal of Pediatric and Adolescent Gynecology ·doi:10.1016/j.jpag.2016.02.008

STUDY OBJECTIVE: Use of gonadotropin-releasing hormone agonists (GnRHa) to treat endometriosis can cause mood and vasomotor side effects. "Add-back therapy," the combination of low-dose hormones, limits side effects but research is limited …

2015
·doi:10.1016/j.jadohealth.2014.10.049
rct 2015
·doi:10.1097/ogx.0000000000000249

Endometriosis often begins during adolescence. Appropriate management includes prompt initiation of therapy and long-term maintenance therapy. Gonadotropin-releasing hormone (GnRH) agonists are commonly used second-line therapy for patients…

rct 2015
Obstetrics and gynecology ·doi:10.1097/aog.0000000000000964

OBJECTIVE: To assess whether add-back therapy with norethindrone acetate or norethindrone acetate plus conjugated equine estrogens is superior to maintain bone health in adolescents and young women using gonadotropin-releasing hormone agoni…

2015
·doi:10.1016/j.jpag.2015.02.008